Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of AZD8108 in Healthy Volunteers
NCT02248818Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Nov 2014
- Primary completion
- Sep 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of AZD8108 in suicidal ideation (4 arms), sponsored by AstraZeneca. Primary endpoints: Thyroid Stimulating Hormone, Area Under the Concentration Curve (0 to Infinity) of AZD6765 and 3 more. Started Nov 2014; status: completed.
02
Drugs
AZD8108
03
Conditions
suicidal ideation
Beyond the preview
Go deeper on NCT02248818.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02248818.